CORDIS
EU research results

CORDIS

English EN
Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection

Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection

Objective

The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.

Coordinator

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Address

Calle Rossello 149 Puerta Bjs
08036 Barcelona

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 070 050

Participants (14)

Sort alphabetically

Sort by EU Contribution

Expand all

ETHERNA IMMUNOTHERAPIES

Belgium

EU Contribution

€ 969 375

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA

Spain

EU Contribution

€ 934 375

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 816 250

VRIJE UNIVERSITEIT BRUSSEL

Belgium

EU Contribution

€ 248 360

THE ROCKEFELLER UNIVERSITY NOT FOR PROFIT CORPORATION

United States

EU Contribution

€ 706 250

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 408 063,75

Simon Fraser University

Canada

EUROPEAN AIDS TREATMENT GROUP EV

Germany

EU Contribution

€ 150 000

UNIVERSIDAD COMPLUTENSE DE MADRID

Spain

EU Contribution

€ 128 750

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

France

EU Contribution

€ 459 276

ASPHALION SL

Spain

EU Contribution

€ 175 000

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 316 236,25

ZABALA INNOVATION CONSULTING, S.A.

Spain

EU Contribution

€ 273 125

AELIX THERAPEUTICS SL

Spain

EU Contribution

€ 30 000

Project information

Grant agreement ID: 731626

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 822 299,13

  • EU contribution

    € 6 685 111

Coordinated by:

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain